Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.33 |
| ▸ | ACE | P12821 | 3/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253965 | 0.82 | POLB (0.36) | KCNH2DYRK1APOLBACE2ACE | |
| SCHEMBL6928468 | 0.81 | CYP11B1 (0.42) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL21514078 | 0.81 | CYP11B1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL13059068 | 0.81 | POLB (0.35) | CYP11B1CYP11B2KCNH2DYRK1APOLB | |
| Hydrochloric Acid SCHEMBL860676 | 0.79 | POLB (0.34) | CYP11B1CYP11B2KCNH2DYRK1APOLB | |
| Hydrochloric Acid SCHEMBL31735658 | 0.79 | POLB (0.34) | KCNH2DYRK1APOLBTOP2A | |
| SCHEMBL14415973 | 0.78 | CYP11B1 (0.33) | CYP11B1CYP11B2KCNH2DYRK1APOLB | |
| SCHEMBL15613574 | 0.78 | CYP11B1 (0.36) | CYP11B1CYP11B2KCNH2DYRK1APOLB | |
| SCHEMBL859620 | 0.78 | — | — | |
| SCHEMBL16886096 | 0.77 | CYP11B1 (0.33) | CYP11B1CYP11B2KCNH2DYRK1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370340-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9192577-B2 | Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
| CN-1279680-A | Imidazole derivatives having farnesyl transferase inhibitory activity and process for producing the same | LG CHEMICAL LTD (KR) | 2001-01-10 | — | — | CN | disclosed |
| EP-1045846-A1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LIMITED (KR) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999028315-A1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD. (KR) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | CYP11B1 715/4885CYP11B2 1015/4885KCNH2 1547/4885 |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | CYP11B1 74/4885CYP11B2 110/4885KCNH2 3827/4885 |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | CYP11B1 715/4885CYP11B2 1015/4885KCNH2 1547/4885 |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | CYP11B1 715/4885CYP11B2 1015/4885KCNH2 1547/4885 |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | CYP11B1 51/4885CYP11B2 47/4885KCNH2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.